在这其中,KEYNOTE-604 研究结果引起了广泛的关注的,因为研究达到了双终点之一的无疾病进展或死亡(PFS), HR = 0.75(95%CI,0.61-0.91, p = 0.0023), 但在另外一个主要终点总生存(OS)上,虽然与对照组相比,展示了明显的获益趋势,中位 OS 得到延长, 试验组 10.8 个月 vs...
我们把KEYNOTE-604、IMpower 133、CASPIAN这三个研究放在一起比较一下:(1)在研究设计方面, IMpower 133、KEYNOTE-604研究终点为双终点PFS和OS, 而CASPIAN为OS单个终点; IMpower133、KEYNOTE-604为随机双盲的Ⅲ 期临床研究, 而CASPIAN为...
KEYNOTE-604 (ClinicalTrials.gov, NCT03066778) evaluates EP plus either pembrolizumab or placebo as first-line therapy for ES-SCLC. Method Not applicable. Result Not applicable. Conclusion In this international, double-blind, phase 3 trial, adults with newly diagnosed ES-SCLC, ECOG PS ≤1, and...
1535TiPKEYNOTE-604: Phase 3 trial of pembrolizumab plus etoposide/platinum (EP) for first-line treatment of extensive stage small-cell lung cancer (ES-SCLC)doi:10.1093/annonc/mdx386.008Rudin, C.M.Shen, L.Pietanza, M.C.Oxford University PressAnnals of Oncology...
604 May 14, 2012 6,525 8,966 Jun 8, 2021 91 Did you noticethat some of the macOS 12 features are only available on the M1 Macs. They’re alreadystarting to drop Intel support in the macOS. guzhogi macrumors68040 Aug 31, 2003 3,806 1,941 Wherever my feet t...
And at that meeting we saw the presentation of 2 trials with PD-1 inhibitors, KEYNOTE-604 with pembrolizumab, and the ECOG-ACRIN 5161 trial, which was actually a phase 2 trial with nivolumab. Can you walk us through those and give us your impressions? Stephen Liu, MD: Yes. These are ...
13.KEYNOTE-604:OS失利,错失一线 三线 14.KEYNOTE-158、KEYNOTE-028:小样本,证据有限 不限瘤种 15.基于生物标记物(MSI-H/dMMR、TMB-H)的第一个“广谱抗癌药” 非小细胞肺癌 拉开序幕 KEYNOTE-001 KEYNOTE-001研究为多队列1期扩大临床研究[1-3],旨在评估帕博利珠单抗治疗晚期肿瘤的有效性和安全性,剂量...
EP: 3.ASCO 2020: Results From the Phase 3 ADAURA Trial EP: 4.ASCO 2020: Results from the Phase 2/3 ZGDH3 Trial Now Viewing EP: 5.ASCO 2019: Results from the Phase 3 KEYNOTE-048 Trial EP: 6.ASCO 2020: Results from the Phase 3 KEYNOTE-604 TrialDownload...
Shitara K, Van Cutsem E, Bang Y, et al. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Rando...